PDF(907 KB)
Advances in research on cutoffs for blood biomarkers in Alzheimer’s disease
Shuheng WANG, Yamei TANG, Jianping JIA
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 337-343.
PDF(907 KB)
Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders
Editor in chief: Jun WANG
PDF(907 KB)
Advances in research on cutoffs for blood biomarkers in Alzheimer’s disease
Blood biomarkers are increasingly used in Alzheimer’s disease (AD). Their clinical use depends on appropriate cutoff definitions and consistent interpretation of results. Current cutoff strategies are mainly based on external reference standards, receiver operating characteristic (ROC) analysis, reference intervals, and population distributions. More recent approaches include ratio-based measures, multi-marker combinations, gray-zone classification, and longitudinal monitoring, particularly when biomarker values fall near the cutoff or when results are interpreted in clinically diverse populations. Biomarker levels may also be influenced by age, apolipoprotein E ε4 genotype, comorbidities, and analytical platform differences, which limit the use of a universal cutoff across different settings. Future studies should move beyond one-time classification toward task-specific interpretation and repeated measurement over time to improve clinical use in screening, diagnosis, and follow-up.
Alzheimer’s disease / Blood biomarkers / Cutoff / Gray zone / Longitudinal monitoring
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer’s disease[EB/OL]. (2025-05-16)[2026-05-07]. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease.
|
| [65] |
|
| [66] |
|
| [67] |
|
利益冲突声明 所有作者在本研究中均不存在利益冲突。
/
| 〈 |
|
〉 |